Pillar® ONCO/Reveal™ Multi-Cancer with CNV and RNA Fusion v2 Panel

The ONCO/Reveal Multi-Cancer with CNV and RNA Fusion Panel is a combined DNA/RNA multi-cancer panel. The assay combines the DNA-based ONCO/Reveal Multi-Cancer v4 with CNV Panel with the ONCO/Reveal Multi-Cancer RNA Fusion v2 Panel allowing for joint sequencing. The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.

Panel highlights

Multiple solid tumor types including NSCLC, thyroid, and prostate 

SNVs, indels, CNVs, and RNA fusions in one product

60 hotspots and 11 CNVs 

Fusions in 18 driver genes plus expression of 14 partners

For research use only. Not for use in diagnostic procedures.

Variants and CNVs detected from DNA

ABL1 CDKN2A FBXW7 GNAS KIT NPM1 PTPN11 SRC
AKT1 CSF1R FGFR1 HNF1A KRAS NRAS RAC1 STK11
ALK CTNNB1 FGFR2 HRAS MAP2K1 NTRK1 RB1 TP53
APC DDR2 FGFR3 IDH1 MET* NTRK2 RET VHL
ATM EGFR* FLT3 IDH2 MLH1 NTRK3 ROS1
BRAF ERBB2* FOXL2 JAK2 MPL PDGFRA SMAD4
CCNE1 ERBB4 GNA11 JAK3 MYC* PIK3CA SMARCB1
CDH1 EZH2 GNAQ KDR NOTCH1 PTEN SMO

CNVs detected and verified by NIST reference standards are indicated by *
CNVs can also be detected in genes indicated by

Fusions and expression insights detected from RNA

Target driver genes Fusion partners
ALK EML4, CLTC, HIP1, KIF5B, KLC1, STRN, TFG, TPM3, TPR, MSN
RET CCDC6, CUX1, KIF5B, NCOA4, TRIM33, PRKARA1, NCOA4
ROS1 CCDC6, CD74, CLTC, EZR, GOPC, LRIG3, MSN, SDC4, SLC34A2, TFG, TPM3
NRG1 CD74, SLC3A2, VAMP2
PBX1 TCF3
FGFR3 TACC3, BAIAP2L1
FGFR2 BICC1, CASP7
EGFR SPET14, PSPH, RAD51, EGFRVIII
NTRK1 TPM3, TFG, LMNA, SQSTM1, CHTOP, ARHGEF2, NFASC, IRF2BP2, PPL, BCAN, SCYL3, TP53, CD74, MPRIP, TPR
NTRK2 AFAP1, NACC2, BCR, TRIM24, QKI, PAN3, SQSTM1
NTRK3 ETV6, BTBD1, EML4, SQSTM1, TFG, RBPMS
BRAF KIAA1549, MKRN1, FAM131B, AKAP9
RAF1 ESRP1, SRGAP3
MET KIF5B, Ex14 skipping
PPARG PAX8, CREB3L2
ERG TMPRSS2
PRKACA DNAJB1
TFE3 SFPQ, ASPSCR1, CLTC, PRCC, NONO
3′/5′ Expression Imbalance Ratio Assessed
ALK ROS1 RET NTRK1 NTRK2 NTRK3 FGFR3 NRG1 PBX1
Expression Control Genes
HMBS TBP

Panel specifications

ONCO/Reveal Multi-Cancer v4 with CNV ONCO/Reveal Multi-Cancer RNA Fusion v2
Enrichment chemistry Multiplex PCR using tiled amplicons Multiplex PCR using tiled amplicons
Number of pools 2 pools 2 pools
Number of genes/amplicons 60/341 18/>80 plus MET 14 exon skipping
Number of targets Hotspots in 60 genes; CNVs for 11 genes Fusions in 18 driver genes; expression for 11 genes
Variant types SNVs, small and medium indels, and CNVs Fusion RNA transcripts
Average amplicon size 125bp (range 86bp – 185bp) 120bp
Recommended input range 5ng to 80ng DNA 10ng to 50ng RNA
Sample types DNA from tissue or blood; FFPE RNA from FFPE or tissue
Mapping rate 99.3% ± 0.3% n/a
% on-target aligned reads 99.5% ± 0.1 % n/a
Coverage uniformity (% targets with >0.2X mean coverage) 98.2% ± 0.7% n/a
Total assay time (from DNA to sequencer) <8 hours <9-10 hours
Sequencing platforms Illumina®, MGISEQ™ and Ion Torrent™ platforms Illumina, MGISEQ and Ion Torrent platforms

Pillar technology

Pillar provides a seamlessly integrated NGS workflow, from panel design to data analysis.

ampPD™

icon of ampPD primer as located on DNA

Primer design platform for reliable amplicon specificity

SLIMamp®

test tube icon

Enrichment chemistry that enables single-tube amplification

PiVAT®

PiVat icon

Bioinformatic tools that deliver sensitive, robust variant calls

Contact an expert

Contact us for technical information or to get a quote

WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top